Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases

Huifeng Yun, Fenglong Xie, John W. Baddley, Kevin Winthrop, Kenneth G. Saag, Jeffrey R. Curtis

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Objective. The protection duration of herpes zoster (HZ) vaccination is unclear among patients with autoimmune (AI) diseases. Methods. Using 2006-2013 Medicare data, HZ vaccinated patients with AI were matched 1:2 to unvaccinated HZ. Incidence rates (IR) and adjusted risk ratios over time were calculated using Poisson regression. Results. Of 59,627 vaccinated patients, crude IR increased from 0.75/100 person-years during the first year post-vaccination to 1.25 during the seventh year. Vaccinated patients had a significantly lower risk of HZ compared with the unvaccinated through 5 years. Conclusion. HZ vaccination was significantly protective only for about 5 years among patients with AI.

Original languageEnglish (US)
Pages (from-to)1083-1087
Number of pages5
JournalJournal of Rheumatology
Volume44
Issue number7
DOIs
StatePublished - Jul 1 2017

Keywords

  • Autoimmune diseases
  • Herpes zoster
  • Infection
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases'. Together they form a unique fingerprint.

  • Cite this